Durable response of therapy-related MDS/AML with concomitant Waldenström’s macroglobulinemia treated with venetoclax and azacitidine
Sign Up to like & getrecommendations! Published in 2022 at "Annals of Hematology"
DOI: 10.1007/s00277-022-04777-z
Abstract: Dear Editor, Venetoclax is an oral drug that is BH3-mimetic and a selective B-cell lymphoma 2 (BCL-2) inhibitor. Inhibition of BCL-2 induces apoptosis in hematological malignancies [1]. Venetoclax has shown activity in patients with acute… read more here.
Keywords: response; therapy related; aml; mds aml ... See more keywords
Role of p53 in regulation of hematopoiesis in health and disease
Sign Up to like & getrecommendations! Published in 2022 at "Current Opinion in Hematology"
DOI: 10.1097/moh.0000000000000715
Abstract: Purpose of review Human aging is associated with an exponential increase in the occurrence of clonal hematopoiesis of indeterminate potential (CHIP). CHIP is associated with increased risks of de novo and therapy-related hematologic neoplasms and… read more here.
Keywords: tp53 mutations; mutant p53; p53; hematopoiesis ... See more keywords
IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?
Sign Up to like & getrecommendations! Published in 2020 at "British Journal of Haematology"
DOI: 10.1111/bjh.16710
Abstract: In this issue, M€ uller-Thomas et al. explored the predictive value of indoleamine 2,3 dioxygenase (IDO) expression in 96 patients with high-risk myelodysplastic syndromes (MDS) and secondary AML (sAML) treated with azacitidine. MDS are clonal… read more here.
Keywords: ido; mds; mds aml; disease progression ... See more keywords
GATA2 deficiency and MDS/AML: Experimental strategies for disease modelling and future therapeutic prospects
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18330
Abstract: The importance of predisposition to leukaemia in clinical practice is being increasingly recognized. This is emphasized by the establishment of a novel WHO disease category in 2016 called “myeloid neoplasms with germline predisposition”. A major… read more here.
Keywords: mds; deficiency mds; gata2 deficiency; aml experimental ... See more keywords
Abstract 127: Efficacy of novel IRAK4 inhibitor CA4948 in AML and MDS
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-127
Abstract: Myelodysplastic syndrome (MDS) & Acute Myeloid Leukemia (AML) are hematologic malignancies that arise from a population of aberrant hematopoietic stem cells (HSCs). Overactivated innate immune signaling pathways such as IRAK1, TRAF6, IL1RAP, S100A9 and IL8… read more here.
Keywords: inhibitor; mds aml; efficacy; mds ... See more keywords
Activation of Cgas-Sting Pathway By Hypomethylating Agent in TP53 Mutated MDS/AML
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-202769
Abstract: Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) carrying TP53 mutation (TP53m) portend an extremely grave prognosis. Conventional treatments, including induction chemotherapy and allogeneic hematopoietic stem cell transplantation, have not been successful in curing these… read more here.
Keywords: treatment; activation; mds aml; cell ... See more keywords
Impact of TP53 Mutation on Outcome after Allogeneic Stem Cell Transplantation for Patients with MDS/AML Not in Complete Remission
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-205849
Abstract: Introduction: The TP53-mutated MDS/AML patients have a dismal prognosis. Even after allo-SCT, the long-term survival remains low, which raises the question of whether these patients should be considered as potential candidates for this approach. Further,… read more here.
Keywords: single hit; tp53 mutation; mds aml; mutation ... See more keywords
County-level analysis reveals two high-incidence regions and potential environmental contributors to myeloid malignancies in Colorado
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-2853
Abstract: Background: Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are hematologic malignancies that result from an accumulation of mutations in the myeloid pathway of hematopoiesis. These diseases are influenced by both intrinsic and extrinsic factors;… read more here.
Keywords: mds aml; adjusted rate; county level; incidence ... See more keywords
Older age and complex karyotype are the main predictors of mortality irrespective of allogeneic transplant in therapy-related myeloid neoplasms: A single‑center retrospective cohort
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5161
Abstract: Therapy-related myelodysplastic syndromes (t-MDS) and acute myeloid leukemias (t-AML) are dramatic late complications of therapies with DNA-damaging agents, with 5-year survival rates around 10%. We retrospectively evaluated 86 patients (pts) diagnosed with t-MDS (N=42), t-MDS/AML… read more here.
Keywords: age; allosct; mortality; related mortality ... See more keywords
Phase 3 Study of ivosidenib (IVO) and azacitidine (AZA) with or without venetoclax in adult patients with newly diagnosed IDH1-mutated AML or MDS/AML ineligible for intensive chemotherapy (EVOLVE-1)
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5192
Abstract: Background: Acute myeloid leukemia (AML) is a clonal hematopoietic stem cell disorder characterized by the infiltration of the bone marrow, peripheral blood, and other tissues by proliferative, immature progenitor cells. Somatic mutations in isocitrate dehydrogenase… read more here.
Keywords: aza; newly diagnosed; aml; mds aml ... See more keywords
Metronomic dose decitabine therapy for TP53 complex karyotype myeloid neoplasms
Sign Up to like & getrecommendations! Published in 2025 at "Blood"
DOI: 10.1182/blood-2025-5227
Abstract: Introduction: Hypomethylating agent and venetoclax (VEN)–based therapy has transformed the treatment landscape for older adults with AML, offering improved remission rates and survival compared to traditional chemotherapy. However, patients with TP53 mutations (TP53mut) and complex… read more here.
Keywords: therapy; lodec ven; aza ven; mds aml ... See more keywords